Atopic dermatitis (AD) is a chronic inflammatory and pruritic skin disease with a worldwide progressive increase in its incidence. In this clinical study, we studied the effect of a cosmetic treatment composed of a cleanser, and a body and face cream, on subjects (babies...
Objective: Yeasts of the Malassezia genus have been extensively studied and correlated with various dermatological diseases such as pityriasisversicolor, seborrheic dermatitis (SD) & dandruff (SD/D), atopic dermatitis, psoriasis, and also less frequently with confluent and reticulated papillomatosis, onyc...
Partager sur Facebook Partager sur Twitter Partager sur Google+ Partager sur LinkedIn Résumé Texte intégral Références Illustrations Compléments 1. Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatmen...
Lynch, P. J., (1994).Dermatology, House Officer Series. Philadelphia: Williams & Wilkins. Nutten, S., (2015). Atopic dermatitis: Global epidemiology and risk factors,Ann Nutr Metab66(suppl 1), 8-16. Lim, H. W., et al. (2017). The burden of skin disease in...
The severity of children's atopic dermatitis (AD) in first grade may predict its persistence in sixth grade, according to a study published online Sept. 19 in the Journal of Dermatology.
Combined with Usnea Barbata and Pulsatilla Koreana, these three extracts are claimed to form a natural preservative system that also has anti-inflammatory effects and might help with skin conditions such as blemishes, atopic dermatitis, and dandruff. On the flip side, Zanthoxylum Piperitum contains...
41 These findings are not just of academic interest because miR-21 is upregulated in multiple human TH2-associated diseases, including eosinophilic esophagitis, atopic dermatitis, and ulcerative colitis.42-44 In addition, miR-21 has been reported to be upregulated in human airway epithelial cells ...
and is the first and only treatment for repigmentation approved for use in the United States. Opzelura is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age an...
Aclaris Therapeutics, Inc. today announced the completion of enrollment into ATI-1777-AD-202, its Phase 2b trial of its investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor, ATI-1777, in patients with mild to severe atopic...
Twitter LinkedIn Facebook Email Print UNION therapeutics A/S, a privately-held, multi-asset, clinical stage, pharmaceutical company focused on immunology and infectious diseases, announced the enrollment of the fir...